Navigation Links
Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease

ANN ARBOR, Mich., Jan. 18, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will host an Alzheimer's disease-focused Investor Day on Tuesday, February 8, 2011 from 3:00-5:00 P.M. (EST) at the Kensington Court Hotel in Ann Arbor, Michigan. Headquartered in Ann Arbor, Adeona's management team welcomes shareholders, potential investors and interested parties to join them for this scientific and corporate update of the Company.

Keynote speaker, George J. Brewer, M.D., Chairman of Adeona's Scientific Advisory Board and the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan, will provide a scientific overview of the roles zinc deficiency and copper toxicity play in patients with Alzheimer's disease and mild cognitive impairment. After the scientific update, James S. Kuo, M.D., M.B.A.., Adeona's Chairman and CEO, will provide an investor update that includes the Company's near-term plans for its zinc-based therapy for Alzheimer's disease and mild cognitive impairment that is being developed as a prescription medical food. The webcast of these presentations will be accessible via the event section on the home page of Adeona's website at

Adeona's management team will greet guests during a reception from 3:00-3:45 P.M., with the scientific and corporate presentations to follow. Attendance at Adeona's Investor Day is limited due to seating availability. People interested in registering to attend should contact the Company by email at or by phone at (734) 332-7800.

The Kensington Court Hotel is located near I-94 and South State Street (Exit #177) along the Briarwood Shopping Mall circle, only 2.5 miles from downtown Ann Arbor and the University of Michigan, and 25 miles from Detroit Metropolitan Airport. The hotel address is: 610 Hilton Blvd., Ann Arbor, MI. 48108.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia, rheumatoid arthritis and age-related macular degeneration. For more information, please visit Adeona's website at

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing and results of our clinical study and our ability to successfully develop products with superior benefits. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of our clinical  trials to be completed on time or to achieve desired results, a failure of our clinical reference laboratory to continue to grow and achieve revenue or a failure by us or our strategic partners to successfully commercialize products and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona to Present at OneMedForum San Francisco 2011 Conference
2. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
3. Adeona Announces Third Quarter 2010 Financial Results and Achievements
4. Adeona to Hold Annual Shareholder Meeting
5. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
6. Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimers Disease and Cognitive Decline
7. Adeona Announces Second Quarter 2010 Profitability and Achievements
8. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
9. Adeona Announces HartLab Expansion Into Microbiology Testing Services
10. NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday, January 12, 2011
11. Watson to Host Investor Day on January 21 in New York City
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Endo International ... Rajiv De Silva , President and CEO, will discuss ... Healthcare Conference in New York on ... . Click on Investor Relations, and then the ... prior to the presentation,s start time to visit the site ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... ... , ... Today, Mothers Against Drunk Driving (MADD) learned that the ... the first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol ... National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
Breaking Medicine News(10 mins):